Unknown

Dataset Information

0

High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.


ABSTRACT: Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with life-threatening toxicity following exposure to the fluoropyrimidine drugs 5-fluorouracil (5-FU) and capecitabine (CAP), widely used for the treatment of colorectal cancer and other solid tumors. The most prominent loss-of-function allele of the DPYD gene is the splice-site mutation c.1905+1G>A. In this study we report the case of a 73-year old woman with metastatic colorectal cancer who died from drug-induced toxicity after the first cycle of 5-FU-containing chemotherapy. Her symptoms included severe neutropenia, thrombocytopenia, mucositis and diarrhea; she died 16 days later despite intensive care measures. Post-mortem genetic analysis revealed that the patient was homozygous for the c.1905+1G>A deleterious allele and several family members consented to being screened for this mutation. This is the first report in Spain of a case of 5-FU-induced lethal toxicity associated with a genetic defect that results in the complete loss of the DPD enzyme. Although the frequency of c.1905+1G>A carriers in the white population ranges between 1 and 2%, the few data available for the Spanish population and the severity of this case prompted us to design a genotyping procedure to prevent future toxic effects of 5-FU/CAP. Since our group had previously developed a high-resolution melting (HRM) assay for the simultaneous detection of KRAS, BRAF, and/or EGFR somatic mutations in colorectal and lung cancer patients considered for EGFR-targeted therapies, we included the DPYD c.1905+1G>A mutation in the screening test that we describe herein. HRM provides a rapid, sensitive, and inexpensive method that can be easily implemented in diagnostic settings for the routine pre-therapeutic testing of a gene mutation panel with implications in the pharmacologic treatment.

SUBMITTER: Borras E 

PROVIDER: S-EPMC3547229 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.

Borràs Emma E   Dotor Emma E   Arcusa Angels A   Gamundi Maria J MJ   Hernan Imma I   de Sousa Dias Miguel M   Mañé Begoña B   Agúndez José A G JA   Blanca Miguel M   Carballo Miguel M  

Frontiers in genetics 20130117


Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with life-threatening toxicity following exposure to the fluoropyrimidine drugs 5-fluorouracil (5-FU) and capecitabine (CAP), widely used for the treatment of colorectal cancer and other solid tumors. The most prominent loss-of-function allele of the DPYD gene is the splice-site mutation c.1905+1G>A. In this study we report the case of a 73-year old woman with metastatic colorectal cancer who died from drug  ...[more]

Similar Datasets

| S-EPMC6360833 | biostudies-literature
| S-EPMC2955237 | biostudies-literature
| S-EPMC7774667 | biostudies-literature
| S-EPMC9264755 | biostudies-literature
| S-EPMC9667542 | biostudies-literature
| S-EPMC4425114 | biostudies-literature
| S-EPMC4568778 | biostudies-literature
| S-EPMC6421267 | biostudies-literature
| S-EPMC3675503 | biostudies-literature
| S-EPMC5309195 | biostudies-literature